Cargando…

Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma

Glioblastoma multiforme (GBM), the most common and deadly brain cancer, exemplifies the paradigm that cancers grow with help from an immunosuppressive tumor microenvironment (TME). In general, TME includes a large contribution from various myeloid lineage-derived cell types, including (in the brain)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Exley, Mark A., Garcia, Samantha, Zellander, Amelia, Zilberberg, Jenny, Andrews, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880446/ https://www.ncbi.nlm.nih.gov/pubmed/35207340 http://dx.doi.org/10.3390/jcm11041069

Ejemplares similares

A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
por: Cultrara, Christopher, et al.
Publicado: (2023)

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
por: Niedbała, Marcin, et al.
Publicado: (2022)

Potential Immunotherapeutics for Immunosuppression in Sepsis
por: Shin, Jinwook, et al.
Publicado: (2017)

The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Immunotherapeutic Approaches for Glioblastoma Treatment
por: Yaghi, Nasser K., et al.
Publicado: (2022)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Immunotherapeutic Intervention against Sarcomas
por: Pedrazzoli, Paolo, et al.
Publicado: (2011)

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer
por: Bazhin, Alexandr V, et al.
Publicado: (2013)

Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
por: Dapash, Mark, et al.
Publicado: (2021)

New Immunotherapeutic Approaches for Glioblastoma
por: Vázquez Cervantes, Gustavo Ignacio, et al.
Publicado: (2021)

Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies
por: Genoud, Vassilis, et al.
Publicado: (2021)

Navigating the Immune Challenge in Glioblastoma: Exploring Immunotherapeutic Avenues for Overcoming Immune Suppression
por: Jain, Prateek, et al.
Publicado: (2023)

Immunotherapeutic potential of Crotoxin: anti-inflammatory and immunosuppressive properties
por: Sartim, Marco Aurélio, et al.
Publicado: (2018)

The role of CMV in glioblastoma and implications for immunotherapeutic strategies
por: Rahman, Maryam, et al.
Publicado: (2018)

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
por: Nesseler, Jean Philippe, et al.
Publicado: (2018)

Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2019)

Current Challenges and Opportunities in Treating Glioblastoma
por: Shergalis, Andrea, et al.
Publicado: (2018)

Immunotherapeutic Challenges for Pediatric Cancers
por: Hutzen, Brian, et al.
Publicado: (2019)

Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research
por: Khansur, Emaad M, et al.
Publicado: (2018)

UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
por: Maich, William, et al.
Publicado: (2023)

Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation
por: Santiago-Sánchez, Ginette S., et al.
Publicado: (2022)

Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma
por: Miska, Jason, et al.
Publicado: (2021)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications
por: Das, Suprava, et al.
Publicado: (2023)

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
por: von Gunten, Stephan, et al.
Publicado: (2023)

Autophagy in the Immunosuppressive Perivascular Microenvironment of Glioblastoma
por: Molina, Maria L., et al.
Publicado: (2019)

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities
por: Lu, Chen, et al.
Publicado: (2019)

Emerging role of ferroptosis in glioblastoma: Therapeutic opportunities and challenges
por: Zhuo, Shenghua, et al.
Publicado: (2022)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
por: Hänsch, Lena, et al.
Publicado: (2023)

Modes of immunosuppression in glioblastoma microenvironment
por: Lehtipuro, Suvi, et al.
Publicado: (2019)

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
por: Kalmuk, James, et al.
Publicado: (2020)

Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules
por: Pinton, Laura, et al.
Publicado: (2020)

Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Publicado: (2022)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
por: Palena, Claudia, et al.
Publicado: (2014)

Immunotherapeutic interventions of Triple Negative Breast Cancer
por: Li, Zehuan, et al.
Publicado: (2018)

The Long Road of Immunotherapeutics against Multiple Sclerosis †
por: Apostolopoulos, Vasso, et al.
Publicado: (2020)

Opportunities and Challenges for Dietary Arsenic Intervention
por: Nachman, Keeve E., et al.
Publicado: (2018)

Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
por: Piper, Keenan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hmfhq0mvqjt2mjh4khicj8k087